These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 27981793)
1. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793 [TBL] [Abstract][Full Text] [Related]
2. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. Iyer SP; Foss FF Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743 [TBL] [Abstract][Full Text] [Related]
3. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586 [TBL] [Abstract][Full Text] [Related]
4. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study. Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027 [TBL] [Abstract][Full Text] [Related]
5. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479 [TBL] [Abstract][Full Text] [Related]
6. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915 [TBL] [Abstract][Full Text] [Related]
7. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119 [TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948 [TBL] [Abstract][Full Text] [Related]
9. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487 [TBL] [Abstract][Full Text] [Related]
10. Romidepsin: in the treatment of T-cell lymphoma. Yang LP Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508 [TBL] [Abstract][Full Text] [Related]
11. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Shustov A; Coiffier B; Horwitz S; Sokol L; Pro B; Wolfson J; Balser B; Eisch R; Popplewell L; Prince HM; Allen SL; Piekarz R; Bates S Leuk Lymphoma; 2017 Oct; 58(10):2335-2341. PubMed ID: 28264616 [TBL] [Abstract][Full Text] [Related]
12. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745 [TBL] [Abstract][Full Text] [Related]
13. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL; J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522 [TBL] [Abstract][Full Text] [Related]
14. Romidepsin for the treatment of T-cell lymphomas. McGraw AL Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158 [TBL] [Abstract][Full Text] [Related]
15. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499 [TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097 [TBL] [Abstract][Full Text] [Related]
18. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013 [TBL] [Abstract][Full Text] [Related]
19. Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD. Brunvand MW; Carson J Hematol Oncol; 2018 Feb; 36(1):340-343. PubMed ID: 28560733 [TBL] [Abstract][Full Text] [Related]
20. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]